Document is current

Article History

Received: 23 June 2024

Accepted: 2 October 2024

First Online: 19 October 2024

Declarations

:

: All the participants were provided written information about the opportunity to collect additional blood and CSF samples for further research analyses, in the BioCogBank© protocol, in accordance with the Declaration of Helsinki. They also provided informed consent for the anonymous use of their clinical data and the results of their CSF and plasma analyses. The “Comité d’Evaluation de l’Ethique des projets de Recherche Biomédicale (CEERB) Paris Nord” (Institutional Review Board-IRB 00006477-of HUPNVS, Paris 7 University, AP-HP), has reviewed and approved the research project entitled «Clinico-biological database of cognitive disorders» (Pr Paquet, principal investigator) on May 30, 2016, and the “Commission Nationale Informatique et Libertés” (CNIL).

: KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). CP Serves at scientific international and national advisory boards and/or as a consultant for Abbvie, Eisai, Roche, Lilly, QWorld, France Alzheimer, Fondation Vaincre Alzheimer, a2MCL association, and Biodimed has given lectures in symposia sponsored by Lilly, Roche, Fujirebio.The other authors report no conflict of interest.